Medical News Today -
19 Feb 2014 12:00
Medtronic, Inc. has announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial, which found that continuous cardiac monitoring with the RevealĀ® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke).
Share this Article